Maryland’s Prescription Drug Affordability Board Shows Success in Lowering Drug Costs

Baltimore, MD, September 26, 2026 — Maryland’s Prescription Drug Affordability Board (PDAB) has reportedly achieved success in its mission to reduce the cost of prescription drugs within the state. The board’s primary strategy involves setting upper payment limits for high-cost prescription medications. This mechanism has been applied to drugs purchased by state and local government entities.

Looking ahead, the PDAB has plans to expand its cost-control measures to encompass private insurance plans. This initiative is characterized as a pioneering effort in the United States, aiming to influence drug pricing on a broader scale. The approach taken by the Maryland board has been noted to mirror strategies being explored or implemented at the federal level concerning drug price negotiation.

The stated objective of the PDAB’s work is to generate significant savings, estimated in the millions of dollars, for both the state of Maryland and its residents. The effectiveness and potential impact of these measures are subject to ongoing observation and analysis.

The board’s actions and future proposals are presented in contrast to existing criticisms within the pharmaceutical pricing landscape. While the summary highlights reported success and future plans, specific details regarding the exact amount of savings realized to date, the specific drugs targeted, or the timeline for extending the program to private insurance were not provided in the summary.

The implementation of such affordability programs often involves complex negotiations with pharmaceutical manufacturers and pharmacy benefit managers. Maryland’s approach is part of a growing national conversation about how to make essential medications more accessible and affordable for the public.

Story summarized from the original created by Vincent DeMarco on marylandmatters.org, see more information here.

Media gallery